DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS, the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: NONE

I hereby claim the benefit under Title 35, United States Code, 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application: U.S. Application Serial No. 08/250,555, filed May 27, 1994 and entitled "A Pharmacological Preparation for the Treatment of Anal Disorders".

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and to file and prosecute any corresponding foreign applications, including any international applications under the Patent Cooperation Treaty or the European Patent Convention: J. David Wharton, Reg. No. 25,717; Don M. Bradley, Reg. No. 22,412; Michael B. Hurd, Reg. No. 32,241; Joan Optican Herman, Reg. No. 31,968; Patrick A. Lujin, Reg. No. 35,260; Michael J. Gross, Reg. No. 35,528; and D. Bartley Eppenauer, Reg. No. 35,499, telephone number (816) 474-6550. Address all correspondence to: SHOOK, HARDY & BACON P.C., One Kansas City Place, 1200 Main Street, Kansas City, Missouri 64105-2118.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's signature:

Stephen R. Gorfine

-le

Residence: Citizenship:

Post Office Address:

New York county, New York United States of America

1215 Fifth Avenue

New York, New York 10029

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231,

PATENT

1114

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

STEPHEN R. GORFINE

Application No. 08/970,447

Filed: November 14, 1997

For: NITRIC OXIDE DONOR

COMPOSITION FOR TREATMENT

OF ANAL DISORDERS

Examiner: Unassigned

Attorney Docket No. 010692-004530US

Art Unit: Unassigned

REVOCATION AND SUBSTITUTION OF

POWER OF ATTORNEY UNDER 37

C.F.R. § 1.36

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.36, Cellegy Pharmaceuticals, Inc. revokes all previous powers of attorney and hereby appoints the following to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

William M. Smith Reg. No. 30,223

Karen B. Dow Reg. No. 29,684

Joe Liebeschuetz Reg. No. 37,505

Margaret A. Powers Reg. No. 39,804

STEPHEN R. GORFINE Application No. 08/970,447 Page 2

Please direct all future correspondence regarding the subject application to:

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834

(415) 576-0200

Date: _Feb.23,1998

Cellegy Pharmaceuticals, Inc.

Title: VPR+)

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

Applicant: GORFINE, Stephen R.
Application No. 08/970,447 Filed: November 14, 1997
For: NITRIC OXIDE DONOR COMPOSITION FOR TREATMENT OF ANAL DISORDERS
CELLEGY PHARMACEUTICALS INC. , a CORPORATION (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
certifies that it is assignee of the patent application identified above by virtue of either:
A. [] An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR
B. [X] A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:
1. From: Stephen R. Gorfine To: Neptune Pharmaceutical Corporation The document was recorded in the Patent and Trademark Office at Reel 7374, Frame 0516, or for which a copy thereof is attached.
2. From: Neptune Pharmaceutical Corporation To: Cellegy Pharmaceuticals, Inc. The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
[X] Copies of assignments or other documents in the chain of title are attached.
The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.
I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.
Date: February 23 1998 Name: Michael L! Francocur
Name: Michael L. Francocus
Title : $VPPY$
Signature :

PATENT ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the person(s) named below (referred to as "ASSIGNOR" whether singular or plural) has solid, assigned, and transferred and does hereby sell, assign, and transfer to Cellegy Pharmaceuticals, Inc., a California corporation, having a place of business at 1065 East Hillsdale Boulevard, Suite 418, Foster City, CA 94404 ("ASSIGNEE"), for itself and its successors, transferres, and assignees, the entire workdwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in United States Letters Patent listed on Schedule A stracked hereto and the patent applications listed on Schedule B attached hereto, together with any reissue, or worldwide, and all rights of priority resulting from the filing in the United States of the patents or patent applications identified on Schedule A or B.

ASSIGNOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

ASSIGNOR agrees to do the following, when requested, and withour further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of antorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that interests herein conveyed. ASSIGNEE desirable for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and coverants with ASSIGNEE that ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Name and Signature

Date of Signature

Signature

Neptuma Pharmaceutical Corporation

By Juphan P. Signature

By Juphan P. Signature

Signature

December 30, 1997

December 30, 1997

December 30, 1997

Country of Men your	
on December 31.1967 before ma spectral Stephen R. Gortine, personally known to me or proved to me of satisfactory evidence to be the person whose name is subscribed in the within instance underged to me that (he/she) executed the same in [his/her] authorized capacity, [his/her] signature on the instrument the person, or the entity upon behalf of which sound, executed the instrument.	Content and
Notary Scal NRIA L KUSCSK Notary Public State of New York No. 4602348 Qualified in Suffolk Country JAN 31,1194	_

SCHEDULEA

Patents

Country	Patent No.	Date of Patent	Title
U.S.A.	5,504 ,117	4/2/ 96	Pharmacologic Preparation for the Treatment of Anal Disorders
U.S.A.	5,69 3,676	1 2/2/97	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders

SCHEDULE R

Patent Applications

		r sneur Whbnesdo	05
Country	Sensi/Appi, No.	Filine Date	Title
<u>Israei</u>	113,448	4/20/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
China	95190687.9	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Korea	700442/199 6	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anni Disorders
Mexico	9 6 0386	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Singapore	9 600 491-6	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Canada	2168247	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anai Disorders
Japan	\$0083 <i>5/</i> 96	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anai Disorders
EPC	95916254.5	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
U.S.A.	0 8/97 0,447	11/14/97	Nitric Oxide Donor Composition for Treatment of Anal Disorders

(0692-00 453045 UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS 604520 WS Washington, D.C. 20231

MAY 27, 1998

PTAS

TOWNSEND AND TOWNSEND AND CREW LLP MARGARET A. POWERS TWO EMBARCADERO CENTER, 8TH FLOOR SAN FRANCISCO, CA 94111-3834



UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILMICORY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER TI REFERENCED BELCW. IT;

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 03/27/1998

REEL/FRAME: 9052/0861

NUMBER OF PAGES: 6

ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

NEPTUNE PHARMACEUTICAL CORPORATION DOC DATE: 12/31/1997

ASSIGNEE:

CELLEGY PHARMACEUTICALS, INC. 1065 EAST HILLSDALE BOULEVARD, SUITE 418 FOSTER CITY, CALIFORNIA 94404

SERIAL NUMBER: 08970447

FILING DATE: 11/14/1997

ISSUE DATE:

SERIAL NUMBER: 08250555

PATENT NUMBER:

FILING DATE: 05/27/1994 ISSUE DATE: 04/02/1996

PATENT NUMBER: 5504117

SERIAL NUMBER: 08666264

FILING DATE: 06/20/1996 ISSUE DATE: 12/02/1997

PATENT NUMBER: 5693676

MAYA BENNETT, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

Re Pa	rm PTO-1595 cordation Form Cover Sheet tents Only ge 2	
1.	Additional name(s) of conveying party(ies): (Continued from Page 1)	
2.	Additional name(s) and address(es) of receiving party(ies): (Continued from Page 1)	
4.	Additional application number(s) or patent number(s): (Continued from Page 1) A. Patent Application No.(s)	B. Patent No.(s) 5,693,676
	E CONTROL OF THE PARTY OF THE P	

PATENT ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the person(s) named below (referred to as "ASSIGNOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Cellegy Pharmaceuticals, Inc., a California corporation, having a place of business at 1065 East Hillsdale Boulevard, Suite 418, Foster City, CA 94404 ("ASSIGNEE"), for itself and its successors, transferres, and assignees, the entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in United States Letters Patent listed on Schedule A attached hereto and the patent applications listed on Schedule B attached hereto, together with any reissue, extension, improvement, division, communation or continuation in-part of any thereof, in the U.S. or worldwide, and all rights of priority resulting from the filing in the United States of the patents or patent applications identified on Schedule A or B.

ASSIGNOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

ASSIGNOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall reasonably consider desirable for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Name and Signature

Neptume Pharmaceutical Corporation

Neptume Pharmaceutical Corporation

By Lephan R Lephan HD

December 30, 1997

[ASSIGNOR NAME]

OTEMALIA. GOEFICE PTA

SCHEDULEA

Patents

Country	Patent No.	Date of Patent	Title '
U.S.A.	5,504,117	4/2/96	Pharmacologic Preparation for the Treatment of Anal Disorders
U.S.A.	5,693,676	1 2/2/97	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders

SCHEDULE B

Patent Applications

		- ishbasadon	•
Country	Serial/Appl. No.	Filing Date	Title
[sma]	113,448	4/20/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
China	95190687.9	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Korea.	700442/199 6	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Mexico	9 6 0386	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Singapore	9 6 00491-6	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Canada	2168247	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Japan	S00835/96	4/10/95	Nime Oxide Donor Composition and Method for Treatment of Anal Disorders
EPC	95916264.5	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
U.S.A.	08/970,447	11/14/97	Nitric Oxide Donor Composition for Treatment of Anal Disorders

Country of New York	
on December 31,1967 before appeared Stephen & Gottine person of satisfactory evidence to be the person whose a saknowledged to me that (he/she) executed the salking signature on the instrument the person actual, executed the insurument.	isme is subscribed to the within instrument and time in This/her] authorized canacity, and that by
Notary Scal NRIA L KUSCSIK	Notary
Notary Public. State of New York No. 4602348	
Outsiffed in Suffolk Courtey VAN 31,194	
~~~	